LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article: Systemic Inflammation Response Index and weight loss as prognostic factors in metastatic pancreatic cancer: A concept study from the PANTHEIA-SEOM trial.

    Pacheco-Barcia, Vilma / Custodio-Cabello, Sara / Carrasco-Valero, Fatima / Palka-Kotlowska, Magda / Mariño-Mendez, Axel / Carmona-Bayonas, Alberto / Gallego, Javier / Martín, A J Muñoz / Jimenez-Fonseca, Paula / Cabezon-Gutierrez, Luis

    World journal of gastrointestinal oncology

    2024  Volume 16, Issue 2, Page(s) 386–397

    Abstract: Background: The prognostic value of the Systemic Inflammation Response Index (SIRI) in advanced pancreatic cancer is recognized, but its correlation with patients´ nutritional status and outcomes remains unexplored.: Aim: To study the prognostic ... ...

    Abstract Background: The prognostic value of the Systemic Inflammation Response Index (SIRI) in advanced pancreatic cancer is recognized, but its correlation with patients´ nutritional status and outcomes remains unexplored.
    Aim: To study the prognostic significance of SIRI and weight loss in metastatic pancreatic cancer.
    Methods: The PANTHEIA-Spanish Society of Medical Oncology (SEOM) study is a multicentric (16 Spanish hospitals), observational, longitudinal, non-interventional initiative, promoted by the SEOM Real World-Evidence work group. This pilot study sought to analyze the association between weight loss and inflammatory status as defined by SIRI. The cohort stems from a proof-of-concept pilot study conducted at one of the coordinating centers. Patients with pathologically confirmed metastatic pancreatic adenocarcinoma, treated from January 2020 to January 2023, were included. The index was calculated using the product of neutrophil and monocyte counts, divided by lymphocyte counts, obtained within 15 days before initiation chemotherapy. This study evaluated associations between overall survival (OS), SIRI and weight loss.
    Results: A total of 50 patients were included. 66% of these patients were male and the median age was 66 years. Metastasis sites: 36% liver, 12% peritoneal carcinomatosis, 10% lung, and 42% multiple locations. Regarding the first line palliative chemotherapy treatments: 50% received gemcitabine plus nab-paclitaxel; 28%, modified fluorouracil, leucovorin, irinotecan and oxaliplatin, and 16% were administered gemcitabine. 42% had a weight loss > 5% in the three months (mo) preceding diagnosis. 21 patients with a SIRI ≥ 2.3 × 10
    Conclusion: A higher SIRI was correlated with decreased survival rates in patients with metastatic pancreatic cancer and associated with weight loss. An elevated SIRI is suggested as a predictor of survival, emphasizing the need for prospective validation in the upcoming PANTHEIA-SEOM study.
    Language English
    Publishing date 2024-02-12
    Publishing country China
    Document type Journal Article
    ZDB-ID 2573696-6
    ISSN 1948-5204
    ISSN 1948-5204
    DOI 10.4251/wjgo.v16.i2.386
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: PO-05 - Incidence of venous thromboembolism (VTE) in bile duct tumors (BDT) treated with chemotherapy in ambulatory setting.

    Adrián, S G / de Castro, E Martínez / Olmos, V Pachóns / Martín, M Navarro / Del Prado, P Martínez / Mena, M Lobo / Ramírez, O Raziel Rúa / Lavín, D Cacho / Arteaga, J F Arango / Martín, A J Muñoz

    Thrombosis research

    2016  Volume 140 Suppl 1, Page(s) S178

    Abstract: Introduction: The incidence of thrombosis associated with pancreatic cancer chemotherapy is high (22-36%), however the incidence in BDT is unknown.: Aim: The aim of this study is to analyze the incidence of incidental and symptomatic VTE, and its ... ...

    Abstract Introduction: The incidence of thrombosis associated with pancreatic cancer chemotherapy is high (22-36%), however the incidence in BDT is unknown.
    Aim: The aim of this study is to analyze the incidence of incidental and symptomatic VTE, and its chronological pattern, in patients with BDT receiving chemotherapy in ambulatory setting.
    Materials and methods: We conducted a retrospective study to determine the incidence of VTE in patients with BDT, treated at 6 hospitals of the Cancer & Thrombosis Working Group of the Spanish Society of Medical Oncology (SEOM). 136 consecutive patients diagnosed and treated with chemotherapy, were identified between January 2008 and December 2012 and included in this analysis.
    Results: Clinical characteristics in Table 1. With a median follow up of 16.6 months (range 0.4-98.2), VTE was identified in 26 patients (19.1%): 10 pulmonary embolism, 9 deep vein thrombosis and 7 visceral vein thrombosis. All VTE occurred in patients with active tumor (2 locally advanced, 24 metastatic). 46% of the events were incidentally diagnosed. 62% of the events occurred in the first 6 months after diagnosis of cancer. Eight events were identified during the diagnostic workup of the neoplasm. Only 1 patient had a VTE recurrence (superficial venous thrombosis). A non-significant trend towards lower survival (OS) in patients with VTE (median OS 20.9 months vs 13.6 months; p=0.066) was observed.
    Conclusions: The incidence of VTE in patients undergoing chemotherapy for BDT in the ambulatory setting is high, but lower than that described in pancreatic cancer.
    Language English
    Publishing date 2016-04
    Publishing country United States
    Document type Journal Article
    ZDB-ID 121852-9
    ISSN 1879-2472 ; 0049-3848
    ISSN (online) 1879-2472
    ISSN 0049-3848
    DOI 10.1016/S0049-3848(16)30138-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 863: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: PO-04 - A new genetic risk score for predicting venous thromboembolic events in cancer patients receiving chemotherapy.

    Martín, A J Muñoz / Ziyatdinov, A / Rubio, V Castellón / Olmos, V Pachón / Huerta, B Morejón / Rodríguez, J Calzas / Fernández, M Salgado / de Castro, E Martínez / Caro, R Luque / Fernández, J M Soria

    Thrombosis research

    2016  Volume 140 Suppl 1, Page(s) S177–8

    Abstract: Background: Venous thromboembolism (VTE) is one of the major causes of cancer-associated mortality. Risk for developing VTE increases when in chemotherapy, mainly in the outpatient setting. Current risk scores for predicting chemotherapy-associated VTE ... ...

    Abstract Background: Venous thromboembolism (VTE) is one of the major causes of cancer-associated mortality. Risk for developing VTE increases when in chemotherapy, mainly in the outpatient setting. Current risk scores for predicting chemotherapy-associated VTE have low/moderate discrimination capacity. These models use clinical parameters. ThromboinCode (TiC) is a new tool for VTE risk prediction using an algorithm that combines a genetic risk score (GRS) with subject's VTE clinical risk parameters (cancer type and cancer disease status "CDS", included).
    Aims: To evaluate whether TiC predicts better the risk for chemotherapy-associated VTE than Khorana score.
    Methods: A prospective, observational study including 251 patients with locally advanced or metastatic cancer (colon, stomach, pancreas and lung) receiving systemic outpatient chemotherapy. Patients are followed-up for 6 months. Three predictive models were compared: a) Khorana score; b) Khorana score plus CDS and c) TiC. Genetic variants included in TiC are FVL, PT, F5 rs118203906 and rs118203905, F12 rs1801020, F13 rs5985, SERPINC1 rs121909548, SERPINEA10 rs2232698 and A1 blood group rs8176719, rs7853989, rs8176743, rs8176750. Clinical risk factors in TiC are age, sex, family history of VTE, BMI, smoking, diabetes, type of cancer and CDS. Prediction capacity of each model was assessed in terms of the discrimination (area under the receiver operating characteristic curve, AUC).
    Results: The incidence of VTE at 6 months was 23.11%. Korana score had an AUC of 0.550 (95% CI 0.485-0.613, p=0.2162), sensitivity 64.41, specificity 46.56, positive likelihood ratio of 1.21, negative likelihood ratio of 0.76. Khorana score+CDS prediction model had an AUC of 0.609 (95% CI 0.545-0.670, p=0.008), sensitivity 70.69, specificity 50.53, positive likelihood ratio of 1.25, negative likelihood ratio of 0.67. Discrimination increased significantly with TiC (AUC: 0.70; 95% CI 0.636 - 0.753, p<0.0001), sensitivity 79.31, specificity 55.44, positive likelihood ratio of 1.78, negative likelihood ratio of 0.37. The discrimination with TiC was significantly higher than with the other two predictive models (p<0.05).
    Conclusions: We conclude that TiC predicts chemotherapy-associated VTE risk significantly better than Khorana score with CDS.
    Language English
    Publishing date 2016-04
    Publishing country United States
    Document type Journal Article
    ZDB-ID 121852-9
    ISSN 1879-2472 ; 0049-3848
    ISSN (online) 1879-2472
    ISSN 0049-3848
    DOI 10.1016/S0049-3848(16)30137-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 863: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top